MX2014004479A - Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades. - Google Patents
Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.Info
- Publication number
- MX2014004479A MX2014004479A MX2014004479A MX2014004479A MX2014004479A MX 2014004479 A MX2014004479 A MX 2014004479A MX 2014004479 A MX2014004479 A MX 2014004479A MX 2014004479 A MX2014004479 A MX 2014004479A MX 2014004479 A MX2014004479 A MX 2014004479A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- oxazine derivatives
- novel oxazine
- novel
- Prior art date
Links
- 150000004893 oxazines Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546836P | 2011-10-13 | 2011-10-13 | |
| US201261695329P | 2012-08-31 | 2012-08-31 | |
| PCT/IB2012/055521 WO2013054291A1 (en) | 2011-10-13 | 2012-10-11 | Novel oxazine derivatives and their use in the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014004479A true MX2014004479A (es) | 2014-08-01 |
Family
ID=47258045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014004479A MX2014004479A (es) | 2011-10-13 | 2012-10-11 | Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9284284B2 (Direct) |
| EP (1) | EP2766358B1 (Direct) |
| JP (1) | JP2014532066A (Direct) |
| KR (1) | KR20140084146A (Direct) |
| CN (1) | CN103987710A (Direct) |
| AU (1) | AU2012322329A1 (Direct) |
| BR (1) | BR112014008686A2 (Direct) |
| CA (1) | CA2851445A1 (Direct) |
| EA (1) | EA201490774A1 (Direct) |
| IN (1) | IN2014DN03206A (Direct) |
| MX (1) | MX2014004479A (Direct) |
| WO (1) | WO2013054291A1 (Direct) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077328A1 (es) | 2009-07-24 | 2011-08-17 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos |
| WO2011154431A1 (en) | 2010-06-09 | 2011-12-15 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| CA2819175C (en) | 2010-12-22 | 2019-01-08 | Janssen Pharmaceutica Nv | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
| RS54782B1 (sr) | 2011-01-13 | 2016-10-31 | Novartis Ag | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja |
| AU2012222394B2 (en) | 2011-03-01 | 2016-06-16 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) |
| EA023824B1 (ru) | 2011-03-09 | 2016-07-29 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE) |
| CN103974940B (zh) * | 2011-12-06 | 2016-08-24 | 詹森药业有限公司 | 5-(3-氨基苯基)-5-烷基-5,6-二氢-2h-[1,4]噁嗪-3-胺衍生物 |
| TW201446758A (zh) | 2013-03-01 | 2014-12-16 | Amgen Inc | 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途 |
| BR112015021336A2 (pt) | 2013-03-08 | 2017-07-18 | Amgen Inc | compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso |
| JP6435321B2 (ja) | 2013-06-12 | 2018-12-05 | ヤンセン ファーマシューティカ エヌ．ベー． | β−セクレターゼ（ＢＡＣＥ）の阻害剤としての４−アミノ−６−フェニル−６，７−ジヒドロ［１，２，３］トリアゾロ［１，５−Ａ］ピラジン誘導体 |
| AU2014280124B2 (en) | 2013-06-12 | 2018-11-01 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (BACE) |
| AU2014280122B2 (en) | 2013-06-12 | 2017-12-21 | Janssen Pharmaceutica Nv | 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE) |
| AU2015301028B2 (en) | 2014-08-08 | 2019-09-26 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US10106524B2 (en) | 2014-12-18 | 2018-10-23 | Janssen Pharmaceutica Nv | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| LT3377488T (lt) | 2015-11-19 | 2023-01-10 | Incyte Corporation | Heterocikliniai junginiai, kaip imunomoduliatoriai |
| EP3828171A1 (en) | 2015-12-22 | 2021-06-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TW201808902A (zh) | 2016-05-26 | 2018-03-16 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MD3472167T2 (ro) | 2016-06-20 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| JOP20190003A1 (ar) * | 2016-07-19 | 2019-01-10 | Novartis Ag | مشتق أوكسازين للاستخدام في الوقاية من مرض ألزهايمر في مرضى عُرضه للخطر |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| WO2018056664A2 (ko) * | 2016-09-22 | 2018-03-29 | 아주대학교산학협력단 | 액상 플라즈마를 포함하는 비만 치료용 조성물 |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| ES2918974T3 (es) | 2016-12-22 | 2022-07-21 | Incyte Corp | Compuestos heteroaromaticos biciclicos como inmunomoduladores |
| MA47120A (fr) | 2016-12-22 | 2021-04-28 | Incyte Corp | Dérivés pyridine utilisés en tant qu'immunomodulateurs |
| BR112019012993A2 (pt) | 2016-12-22 | 2019-12-03 | Incyte Corporation | derivados de benzo-oxazol como imunomoduladores |
| DK4212529T3 (da) | 2018-03-30 | 2025-04-07 | Incyte Corp | Heterocykliske forbindelser som immunmodulatorer |
| RS64188B1 (sr) | 2018-05-11 | 2023-06-30 | Incyte Corp | Tetrahidro-imidazo[4,5-c]piridin derivati kao pd-l1 imunomodulatori |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| EP4037773A1 (en) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| CA3160131A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CN110950865B (zh) * | 2019-12-16 | 2022-05-17 | 诚达药业股份有限公司 | 一种医药中间体8-氯-1,7-萘啶-3-甲醛合成方法 |
| CN110885329B (zh) | 2019-12-16 | 2020-12-15 | 诚达药业股份有限公司 | 一种1,7-萘啶衍生物的合成方法 |
| CN112250580A (zh) * | 2020-10-28 | 2021-01-22 | 上海昂卓新材料科技有限公司 | 一种2-硝基-2-取代苯基丙烷-1,3-二醇的制备方法 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| EP4240739A1 (en) | 2020-11-06 | 2023-09-13 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| MXPA05012465A (es) | 2003-05-20 | 2006-01-30 | Novartis Ag | Heterociclos de nitrogeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma. |
| EP1853573A1 (en) | 2005-02-25 | 2007-11-14 | Rigel Pharmaceuticals, Inc. | Benzisothiazoles useful for treating or preventing hcv infection |
| CA2628074C (en) * | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
| WO2008133273A1 (ja) * | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
| WO2010063718A1 (en) | 2008-12-02 | 2010-06-10 | ETH Zürich | Screening assay for metabolic disease therapeuticals |
| AR077328A1 (es) * | 2009-07-24 | 2011-08-17 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| JPWO2011058763A1 (ja) * | 2009-11-13 | 2013-03-28 | 塩野義製薬株式会社 | アミノリンカーを有するアミノチアジンまたはアミノオキサジン誘導体 |
| US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| WO2011154431A1 (en) | 2010-06-09 | 2011-12-15 | Janssen Pharmaceutica Nv | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| EP2663559B1 (en) | 2011-01-12 | 2015-07-01 | Novartis AG | Oxazine derivatives and their use in the treatment of neurological disorders |
| RS54782B1 (sr) | 2011-01-13 | 2016-10-31 | Novartis Ag | Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja |
| WO2012095521A1 (en) | 2011-01-13 | 2012-07-19 | Novartis Ag | Bace-2 inhibitors for the treatment of metabolic disorders |
| US9242943B2 (en) | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
| US8399459B2 (en) | 2011-02-02 | 2013-03-19 | Hoffmann-La Roche Inc. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
-
2012
- 2012-10-11 EA EA201490774A patent/EA201490774A1/ru unknown
- 2012-10-11 BR BR112014008686A patent/BR112014008686A2/pt not_active Application Discontinuation
- 2012-10-11 CA CA2851445A patent/CA2851445A1/en not_active Abandoned
- 2012-10-11 KR KR1020147012410A patent/KR20140084146A/ko not_active Withdrawn
- 2012-10-11 AU AU2012322329A patent/AU2012322329A1/en not_active Abandoned
- 2012-10-11 CN CN201280060971.4A patent/CN103987710A/zh active Pending
- 2012-10-11 US US14/350,938 patent/US9284284B2/en active Active
- 2012-10-11 EP EP12791856.3A patent/EP2766358B1/en not_active Not-in-force
- 2012-10-11 MX MX2014004479A patent/MX2014004479A/es unknown
- 2012-10-11 IN IN3206DEN2014 patent/IN2014DN03206A/en unknown
- 2012-10-11 JP JP2014535212A patent/JP2014532066A/ja active Pending
- 2012-10-11 WO PCT/IB2012/055521 patent/WO2013054291A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014532066A (ja) | 2014-12-04 |
| US9284284B2 (en) | 2016-03-15 |
| AU2012322329A1 (en) | 2014-05-01 |
| KR20140084146A (ko) | 2014-07-04 |
| IN2014DN03206A (Direct) | 2015-05-22 |
| US20140256715A1 (en) | 2014-09-11 |
| EA201490774A1 (ru) | 2014-08-29 |
| EP2766358B1 (en) | 2016-06-22 |
| WO2013054291A1 (en) | 2013-04-18 |
| CA2851445A1 (en) | 2013-04-18 |
| EP2766358A1 (en) | 2014-08-20 |
| BR112014008686A2 (pt) | 2017-04-25 |
| CN103987710A (zh) | 2014-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014004479A (es) | Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades. | |
| TN2013000285A1 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
| TN2014000062A1 (en) | 2 -amino-4 - (pyridin- 2 -yl) - 5, 6 -dihydro-4h- 1, 3 -oxazine derivatives and their use as bace-1 and/or bace - 2 inhibitors | |
| MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
| MX2012001070A (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos. | |
| IN2012DN01233A (Direct) | ||
| EA201391029A1 (ru) | Производные оксазина и их применение при лечении неврологических нарушений | |
| PH12013501600A1 (en) | Novel heterocyclic derivatives | |
| MX2013007558A (es) | 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2). | |
| PH12013502156A1 (en) | 1,3-oxazines as bace1 and/or bace2 inhibitors | |
| MX2013014007A (es) | [1,3] oxazinas. | |
| MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
| PH12013502316A1 (en) | Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors | |
| PH12012500622A1 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| HK1206597A1 (en) | Spirocyclic dihydro-thiazine and dihydro-oxazine bace inhibitors, and compositions and uses thereof | |
| PH12014501334A1 (en) | Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines | |
| EA201390984A1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии | |
| WO2013040227A3 (en) | Therapeutic compounds | |
| MX2012008328A (es) | Derivados de pirazina. | |
| NZ702254A (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| CA2863110A1 (en) | 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators | |
| TN2011000668A1 (en) | Oxazine derivatives and their use as bace inhibitors for the treatment of neurological disorders | |
| TN2013000327A1 (en) | Novel heterocyclic derivatives |